TAK-683 is an investigational peptide analogue of metastin that has been shown preclinically to be a potent metastin/GPR54 agonist both in vitro and in vivo. Administration of TAK-683 to male rats for 4 or 8 weeks has been shown to deplete GnRH in the hypothalamus and to reduce plasma FSH, LH and testosterone concentrations. The metastin analogue TAK-683 may be a promising candidate for further investigation in clinical trials in prostate cancer. A related metastin analogue, TAK-448, is also being evaluated in animal studies and in phase 1 clinical trials in prostate cancer References: Endo N, Tamesaki C, Ohkura S, Wakabayashi Y, Matsui H, Tanaka A, Watanabe T, Okamura H, Tanaka T. Differential changes in luteinizing hormone secretion after administration of the investigational metastin/kisspeptin analog TAK-683 in goats. Anim Reprod Sci. 2015 May 29. pii: S0378-4320(15)00129-3. doi: 10.1016/j.anireprosci.2015.05.016. [Epub ahead of print] PubMed PMID: 26051610.

纯度：≥98%

CAS：872719-49-8